Showing 4011-4020 of 4164 results for "".
- Aurinia Completes Patient Enrollment In Phase 2/3 Trial of Voclosporin for the Treatment of Dry Eyehttps://modernod.com/news/aurinia-completes-patient-enrollment-in-phase-2-3-trial-of-voclosporin-for-the-treatment-of-dry-eye/2477914/Aurinia Pharmaceuticals announced it has completed enrollment for the phase 2/3 AUDREY clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Voclosporin’s proven mechanism of action as a novel calcineurin inhibitor gives us
- Iveric Bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings for GA Secondary to AMDhttps://modernod.com/news/iveric-bio-announces-positive-zimura-18-month-data-supporting-the-12-month-efficacy-findings/2479517/Iveric bio announced positive 18 month results from the company’s first phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The 18 month data support
- Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidatehttps://modernod.com/news/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate/2477889/Johnson & Johnson announced that through its Janssen Pharmaceutical Companies division that it has accelerated the initiation of the phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Initially scheduled to begin in September, the tri
- Zeiss Announces 3 Million Eyes Treated With SMILEhttps://modernod.com/news/zeiss-announces-3-million-eyes-treated-with-smile/2477881/Zeiss Medical Technology announced a new milestone with more than 3 million treated eyes with SMILE in more than 1,000 clinics worldwide. SMILE, which became commercially available in the United States in 2017, is a minimally-invasive corneal refractive procedure performed by using the Vi
- Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-first-phase-3-trial-of-ncx-470-in-glaucoma/2477855/Nicox announced the initiation of the first phase 3 clinical trial, Mont Blanc, evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension, by enrolling the first 12 patients. NCX 470 is the company’s novel, second-generation nitric oxide (NO)-donating
- NIH to Test Hydroxychloroquine, Azithromycin Combination as Potential COVID-19 Treatmenthttps://modernod.com/news/nih-to-test-hydroxychloroquine-azithromycin-combination-as-potential-covid-19-treatment/2477775/The US National Institutes of Health (NIH) said Thursday that it is launching a clinical trial evaluating the combination of hydroxychloroquine plus azithromycin to treat patients with mild-to-moderate COVID-19 in the US. Anthony Fauci, director of the NIH’s National Institute of Allergy an
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- Oculis to Present Results From Its Phase 2 Trial of OCS-01 for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-to-present-results-from-its-phase-2-trial-of-ocs-01-for-inflammation-and-pain-following-cataract-surgery/2477721/Oculis announces that it will present results from its phase 2 (SKYGGN) clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, at the American Society of Cataract and Refractive Surgery (ASCRS) annual
- AI-Supported Test Can Detect Glaucoma Progression 18 Months Earlierhttps://modernod.com/news/ai-supported-test-can-detect-glaucoma-progression-18-months-earlier/2477706/A new test can detect glaucoma progression 18 months earlier than the current gold standard method, according to results from a clinical trial sponsored by the University College London (UCL). The technology, supported by an artificial intelligence (AI) algorithm, could help accelerate cli
- iSTAR Medical: Biocompatible MIGS Implant Shows Outstanding Efficacy in Glaucoma Patientshttps://modernod.com/news/istar-medical-biocompatible-migs-implant-shows-outstanding-efficacy-in-glaucoma-patients/2477668/iSTAR Medical announced positive results from two clinical trials of its micro-invasive glaucoma surgery (MIGS) implant MINIject. Both studies showed consistent reduction of IOP and reduced need for IOP-lowering medication in over 50 patients with open angle glauco